<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380315</url>
  </required_header>
  <id_info>
    <org_study_id>AG1321001_P302</org_study_id>
    <nct_id>NCT00380315</nct_id>
  </id_info>
  <brief_title>Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher</brief_title>
  <official_title>Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 Capsule as an Anti-Tussive Agent in Cough Patients: Double Blinded, Randomized, Placebo and Active Rug Comparative, Parallel Designed Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahn-Gook Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ahn-Gook Pharmaceuticals Co.,Ltd</source>
  <brief_summary>
    <textblock>
      This study is for therapeutic confirmation of AG1321001 to evaluate the safety and efficacy&#xD;
      as an anti-tussive agent in cough patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cough severity, Cough specific Quality of Life</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily cough symptom, Cough frequency</measure>
  </secondary_outcome>
  <enrollment type="Actual">396</enrollment>
  <condition>Cough</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG1321001(drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult between the ages of 18 and 70.&#xD;
&#xD;
          2. Patient who has cough symptom caused by following diseases: chronic bronchitis,&#xD;
             bronchiectasis, gastroesophageal reflux disease, postnasal drip syndrome caused by&#xD;
             rhinitis, sinusitis, rhinopharyngitis, rhinolaryngitis.&#xD;
&#xD;
          3. Patient requiring internal treatment due to cough symptom, who has coughing more than&#xD;
             3 weeks.&#xD;
&#xD;
          4. patient who will continue to cough more than 1 week.(by physician's judgment)&#xD;
&#xD;
          5. Patient who decided to participate in this clinical trial at his(her) own will and&#xD;
             agreed in written letter of consent.&#xD;
&#xD;
          6. Patient who is trustworthy, ready for cooperation and observing the restrictions&#xD;
             during the trial period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who is accompanied by the seriously abnormal symptom in respiratory system,&#xD;
             such as Acute infectious Pulmonary Disease, Tuberculosis.&#xD;
&#xD;
          2. Patient who has clinical history of sensitivity to Xanthine drug.&#xD;
&#xD;
          3. Patient who has Peptic Ulcer or Asthma (Except Cicatrix)&#xD;
&#xD;
          4. Patient whose liver or kidney function is seriously abnormal: Including the cases of&#xD;
             sGOT, sGPT, bilirubin and blood creatinine value exceeding twice of their upper normal&#xD;
             limit.&#xD;
&#xD;
          5. Patient whose heart function is abnormal: including the case of showing abnormal EKG&#xD;
             test value that is clinically significant.&#xD;
&#xD;
          6. Patient who has experience to have participated in other clinical trial within two&#xD;
             months before starting the trial.&#xD;
&#xD;
          7. Pregnant woman, lactating woman.&#xD;
&#xD;
          8. patient who has convulsion or alcoholism.&#xD;
&#xD;
          9. patient who take medicines which can not use combination with AG1321001.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-hwan Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital, Seoul, 110-744, Korea, Republic of</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Choon-Taek Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital, Sungnam, Korea, Republic of</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hee-Soon Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Boramae Hospital, Seoul, 156-707, Korea, Republic of</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki-suk Jung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Sacred Heart Hospital, Anyang, Kyunggi, 430-070, Korea, Republic of</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joon Chang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital, Seoul, 120-752, Korea, Republic of</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chul-min Ahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yongdong Sevenrance Hospital, Seoul, 135-720, Korea, Republic of</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>82</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.ahn-gook.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2006</study_first_posted>
  <last_update_submitted>June 30, 2009</last_update_submitted>
  <last_update_submitted_qc>June 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jung Hoon Han / Project Development Team</name_title>
  </responsible_party>
  <keyword>Cough</keyword>
  <keyword>Chronic bronchitis</keyword>
  <keyword>PNDs</keyword>
  <keyword>Post Nasal Drip syndrome</keyword>
  <keyword>GERD</keyword>
  <keyword>gastroesophageal reflux disease</keyword>
  <keyword>bronchiectasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

